<DOC>
	<DOC>NCT01168206</DOC>
	<brief_summary>The association of nutritional supplement TK3 to conventional treatment of cancer patients reduces the intensity and frequency of toxic effects and side effects caused by adjuvant or palliative treatments for the protection of healthy tissues, resulting in a better quality of life.</brief_summary>
	<brief_title>Evaluation of TK3 in Improving Quality of Life in Patients With Malignancy Under Chemotherapy</brief_title>
	<detailed_description />
	<criteria>Patient Consent: Informed Consent and informed consent signed and dated by the patient (or his legal representative) and the professional who has obtained the consent. Must be delivered before inclusion. This term must be read and explained to the patient. Patients female or male, regardless of race or color.Able to ingest oral medication. Patients 3080 years, with malignancy, clinical stage III or IV on chemo or hormone therapy. Patients who have a Karnofsky level between 60 and 80. no agreement to sign the Deed of Consent. Need for use of parenteral nutrition. The need for food supplement already approved. Inability to receive the drug orally. Participation in another clinical trial involving chemotherapy drugs. Women being sexually active, which does not agree to adhere to the contraceptive methods adopted. Women lactating Any problem or condition that the investigator in the trial could be harmful to the patient.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>